| Clinical Research Coordinator for multiple inpatient and outpatient, acute and chronic cardiology trials (phases II-III).
Subinvestigator: “Comparison of XXX plus XXX Given as a Fixed Dose or on a Weight Optimized Basis for Treatment of Chronic Hepatitis C in Previously Untreated Adult Subjects”
Subinvestigator: “A Prospective, Randomized, Multicenter, Open Label, Comparitive Safety Study of XXX versus XXX plus XXX Treatment versus a 12 Week Treatment Delay in Patients with Chronic Hepatitis C”
Subinvestigator: “Limited Access Protocol for the Use of XXX in the Treatment of Gastroesophageal Reflux Disease and other Gastrointestinal Motility Disorders”
Subinvestigator: “Evaluation of Postoperative Outcomes Using Harmonic Scalpel versus Electrocautery for Tonsillectomy”. An Investigator-initiated study
Subinvestigator: “Randomized, Double-Blind, Placebo-Controlled Trial of XXX, XXX, and XXX plus XXX in Patients with Seasonal Allergic Rhinitis”
Subinvestigator: “A Multicenter, Randomized, Double-Blind study to Evaluate the Safety and Efficacy of XXX once daily for 5 days versus XXX once daily for 10 days in the Treatment of Acute Bacterial Sinusitis in Adults”
Subinvestigator: “A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of XXX in the Treatment of Xerostomia Secondary to Radiation Therapy for Cancer in the Head and Neck Region”
Subinvestigator: “Nasal Obstruction and Septoplasty Effectiveness Trial”
Subinvestigator: “A Pilot, Multicenter, Open-Label, Non-Comparative Study of the Safety and Efficacy of XXX in the Treatment of Acute Otitis Media Twice Daily for Seven Days in Children with Tympanostomy tubes”
Subinvestigator: “A Multicenter, Randomized, Comparative Study to Evaluate the Efficacy and Safety of XXX in the Treatment of Children Who Have Recurrent and/or Persistent Acute Otitis Media”
Subinvestigator: “A Multicenter, Long-Term, Active-Surveillance Study of Musculoskeletal Disorders That Occur After Initiating a Course of XXX or XXX Therapy for Acute Infectious Diseases in Children Who Were Enrolled in Phase 3 Clinical Trials Involving XXX”
Subinvestigator: “A Phase III, Open Label, Long-Term Safety Surveillance Study of XXX in Patients with Xerostomia Secondary to Radiation Therapy for Cancer in the Head and Neck Region”
Subinvestigator: “A Randomized, Double-Blind, Placebo-Controlled Trial of XXX and XXX plus XXX in Patients with Seasonal Allergic Rhinitis”
Subinvestigator: “A Randomized, Double-Blind, Placebo-Controlled Trial of XXX at a Dosage of One Spray per Nostril Twice Daily in Patients With Seasonal Allergic Rhinitis”
Subinvestigator: “A Phase II, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of the Effects of XXX on Oral Mucositis in Patients Receiving Radiation Therapy for Carcinoma of the Oral Cavity, Oropharynx, or Nasopharynx”
Subinvestigator: “A Multicenter, Randomized, Double-Blind, Double-Dummy Comparative Trial if XXX versus XXX for the Treatment of Acute Bacterial Maxillary Sinusitis in Adults Undergoing Diagnostic Sinus Aspiration”
TRAINING: 3/20/02 “Human Participants Protection Education for Research Teams” online course sponsored by the National Institutes of Health
7/9/02 “Transportation of Dangerous Goods”. Completed training and testing for the handling/offering for transport/transporting of dangerous goods per 49CFR 172.700. Training good for 2 years.
|
